Financial reports
10-K
2023 FY
Annual report
28 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
28 Feb 22
Current reports
8-K
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
28 Feb 24
8-K
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides
8 Nov 23
8-K
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
8 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
21 Jun 23
8-K
Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
8 May 23
8-K
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
28 Feb 23
8-K
Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
7 Nov 22
8-K
Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
8 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
21 Jun 22
8-K
Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
10 May 22
Registration and prospectus
POS AM
Prospectus update (post-effective amendment)
10 May 22
POS AM
Prospectus update (post-effective amendment)
28 Feb 22
POSASR
Automatic shelf registration (post-effective amendment)
28 Feb 22
S-3ASR
Automatic shelf registration
24 Nov 21
S-8
Registration of securities for employees
30 Oct 20
424B4
Prospectus supplement with pricing info
30 Oct 20
S-1MEF
Registration of additional securities for an S-1
29 Oct 20
S-1/A
IPO registration (amended)
26 Oct 20
8-A12B
Registration of securities on exchange
26 Oct 20
S-1/A
IPO registration (amended)
22 Oct 20
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Jun 23
DEFA14A
Additional proxy soliciting materials
25 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
20 May 21
DEFA14A
Additional proxy soliciting materials
29 Apr 21
Other
EFFECT
Notice of effectiveness
13 May 22
EFFECT
Notice of effectiveness
30 Oct 20
CORRESP
Correspondence with SEC
29 Oct 20
CERT
Certification of approval for exchange listing
28 Oct 20
CORRESP
Correspondence with SEC
27 Oct 20
CORRESP
Correspondence with SEC
27 Oct 20
SEC STAFF
SEC staff action: Order
27 Oct 20
UPLOAD
Letter from SEC
27 Oct 20
SEC STAFF
SEC staff action: Order
23 Oct 20
UPLOAD
Letter from SEC
16 Jul 20
Ownership
SC 13G/A
EcoR1 Capital, LLC
15 Feb 24
SC 13G/A
EcoR1 Capital, LLC
15 Feb 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Sommadossi Jean-Pierre
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
BML Investment Partners, L.P.
7 Feb 24
SC 13G
BML Investment Partners, L.P.
7 Feb 24
4
Andrea Corcoran
2 Feb 24
4
Jean-Pierre Sommadossi
2 Feb 24